WORLDWIDE MARKETING TECHNOLOGIES INC. ANNOUNCES COMPLETION OF MERGER WITH CELL SCAN INTERNATIONAL INC.

    /24-7PressRelease/ - MIAMI, FL, July 05, 2007 - CSI is involved in the introduction in Africa of a new drug for the treatment of HIV, a new formulation for a Malaria drug, also a distributor of certain drugs to the government of Africa. Also Cell Scan International, Inc. is currently in the development stage of a new human pain killer drug for the US and European markets.

CELL SCAN PHARMA INC. will be the name of the corporation surviving this merger. Cell Scan Pharma Inc. will immediately cease all advertising activities and dispose of the advertising portion of the business. Cell Scan Pharma Inc. will proceed strictly as a pharmaceutical company developing and marketing pharmaceutical products for both human and veterinarian use on worldwide markets. The new board of directors and merger group have already been working on the restructure of the company to effectively and profitably operate as a fully pharmaceutical company in both the human and veterinarian world markets.

Cell Scan International, Inc. has been in the human pharmaceutical industry for years and has developed HIV drugs that will be introduced this year in Africa also a new formula for a malaria drug. Also Cell Scan International, Inc. is currently a supplier to the African Government for certain drugs which the activities and revenues will be integrated into the new company along with existing sales and revenues for importation and distribution of a human medical device known as the synvisc and hyalgan. Sales in 2006 were substantial.

The new board of directors will be Robert C Roy, PhD, as Chairman, Idris Badmus PhD as Vice president and secretary, Mr. Michael DeMeo as CFO and Mr. Rudolf Krause as Treasurer all having many years of experience.

The pre merger company was trading at around 0.42 euro, with the merger a roll back 1 for 10 shares for worldwide shareholders, will bring the introduction price of the integrated merger corporation that will trade now under Cell Scan Pharma Inc. at 4.2 euro, close to the 504 reg D filing document done by Cell Scan International Inc. last January 2007. The total outstanding shares after merger will be 29,704,333 shares

The Company's board of directors has further approved, due to the name change, a mandatory exchange of Worldwide Marketing Technologies Inc. certificates and Cell Scan International Inc. for Cell Scan Pharma Inc. certificates. All current holders of Worldwide Marketing Technologies Inc and Cell Scan International Inc. shares are required to physically return their certificates to the company's transfer agent in exchange for new certificates issued and tradable under the Cell Scan Pharma Inc. name and cusip.

Information presented in this newsletter contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as "projects", "foresee", "expects'", "will," "anticipates," "estimates," "believes," "understands" or that by statements indicating certain actions "may," "could," or "might" occur.

CONTACT: Investor Relation
Michael DeMeo, CFO 954 415 7677
http://www.cellscaninter.com
[email protected]

# # #